NasVax Ltd.'s VaxiSome, a novel adjuvant/delivery system for enhacing the activity of existing vaccines, consists of lipid assemblies comprising an innovative, proprietary family of positively charged polycationic lipids. The technology generates strong adjuvant activity, with the potential for intranasal, intramuscular, or subcutaneous administration. This platform can also be applied to boost the bioactivity of various immunomodulators, such as a broad spectrum of well-established adjuvants and cytokines.
Kiryat Weizmann, Science Park
POB 4122
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.